Hematologic Oncology

Progress in our understanding of multiple myeloma pathogenesis has led to the identification of new therapeutic targets.

The FDA announced that brentuximab vedotin has been approved for the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

Diffuse large B-cell non-Hodgkin lymphoma is typically a chemotherapy-sensitive malignancy, justifying dose-intense therapy with hematopoietic stem cell transplantation for patients unlikely to achieve cure with standard-dose regimens.

Treating myelofibrosis with the investigational JAK inhibitor ruxolitinib holds promise.

A look at dramatic changes in the landscape of multiple myeloma that have occurred over the past decade and new developments in the context of stem cell transplantation in non-Hodgkin lymphoma.

Intense research has resulted in JAK-STAT becoming one of the best-understood signal transduction cascades.

Srdan Verstovsek, MD, PhD, is a medical oncologist and associate professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center in Houston.

Every decade during the past 50 years, treatment for multiple myeloma has taken a leap forward.

Ruxolitinib, an investigational JAK inhibitor, demonstrated significant benefits for patients with myelofibrosis.

Reynaldo Garcia From Lineberger Comprehensive Cancer Center on CML BCR-ABL Testing Recommendation

ODAC unanimously recommended accelerated approval for brentuximab vedotin (Adcetris) in 2 types of lymphoma.

It was midnight and I had just been jarred out of a sound sleep by the startlingly repetitive beeping of my pager.

Extracorporeal photopheresis takes approximately 3 to 4 hours to complete and involves leukapheresis, separation of the buffy coat, photoactivation, and finally reinfusion.

Dr. Sonali Smith director Lymphoma Program at the University of Chicago Medical Center Discusses Lymphoma in the Elderly

FDA digest from June discussing warning labels, pancreatic treatment choices, and the quest for a lymphoma drug.

Tips for success from Lawrence B. Afrin, MD an associate professor of medicine in the Division of Hematology/Oncology at Medical University of South Carolina in Charleston.

The FDA has granted accelerated approval for Istodax (romidepsin) to be used as treatment for an aggressive form of non-Hodgkin lymphoma

Dr Kris From Memorial Sloan-Kettering Cancer Center Discusses Methotrexate in Acute Lymphocytic Leukemia

Hematologic cancer resources gathered from across the web including a news brief, patient education, clinical trials and CME/CE

Amonafide+Cytarabine may not be effective for secondary acute myeloid leukemia, according to ACCEDE trial data

High doses of methotrexate increases EFS for children and young adults

Researchers at North Carolina State University used canines as genetic models for studying lymphomas

Reynaldo Garcia from the UNC Lineberger Comprehensive Cancer Center Explains the BCR-ABL Study

Reynaldo Garcia from the University of North Carolina Lineberger Comprehensive Cancer Center on BCR-ABL Testing in Chronic Myelogenous Leukemia

Oncologist James Berenson, MD, likes all of his patients, especially the ones with whom he skis.